The stock prices of companies developing gene therapies are surging on optimism that one-shot treatments will cure a host of rare, inherited diseases, so let’s take a moment to remember gene therapy is risky and prone to failure.

At an FDA advisory panel last week, kids with a rare and debilitating form of severe night blindness told emotional, joyous stories of seeing rainbows and playing outside with their friends at dusk for the first time because of a groundbreaking gene therapy called Luxturna developed by Spark Therapeutics (ONCE). As I noted on Twitter, the patient testimonies at the Luxturna advisory panel ranked among the most compelling I’ve ever heard, and underscore the incredible potential for gene therapy to change lives for the better.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy